| Field | Specification |
|---|---|
| UniProt # | |
| Applications | |
| Sensitivity | |
| Detection range | |
| Detection method | |
| Assay time | |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Scientific Background
This ELISA kit applies to the in vitro quantitative determination of Human FGF23 concentrations in serum, plasma and other biological fluids.
Assay Principle
This ELISA kit uses the Sandwich-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Human FGF23. Standards or samples are added to the micro ELISA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human FGF23 and Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human FGF23, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The OD value is proportional to the concentration of Human FGF23. You can calculate the concentration of Human FGF23 in the samples by comparing the OD of the samples to the standard curve.
Performance Specifications
| Sensitivity | 9.38 pg/mL |
|---|---|
| Detection Range | 15.63-1000 pg/mL |
| Total Assay Time | 3 h 30 min |
| Compatible Sample Types | Serum, plasma and other biological fluids |
| Species Reactivity | Human |
| Detection Method | Sandwich |
| Precision (CV) | Both intra-CV and inter-CV are < 10%. |
| Recovery Rate | 80%-120% |
| Storage | 2-8℃,12 months |
✓ Research-Grade Validation
Specificity
This kit recognizes Human FGF23 in samples. No significant cross-reactivity or interference between Human FGF23 and analogues was observed
Safety & Regulatory
Handle reagents in accordance with institutional biosafety guidelines. Refer to the Safety Data Sheet (SDS) for complete hazard and handling information. Contains components that may require special disposal procedures per local regulations.
This kit is validated for use with Serum, plasma and other biological fluids. For unlisted matrices (e.g., tissue lysate, urine), perform a spike-and-recovery experiment to confirm assay performance before generating reportable data. Sample dilution in the kit's provided diluent is recommended to minimize matrix interference.
The minimum detectable concentration (sensitivity) of this kit is 9.38 pg/mL. Values below this threshold should be reported as below the limit of detection (<LOD) and should not be extrapolated from the standard curve.
The total assay time from sample addition to absorbance reading is approximately 3 h 30 min, including all incubation, wash, and substrate steps. Hands-on time is typically 1–2 hours; most steps involve passive plate incubation. Plan the assay as a single uninterrupted session for best results.
Standard components of this Sandwich ELISA Kit typically include: pre-coated microplate (96-well strip format), lyophilized or liquid recombinant FGF23 standard, detection antibody, streptavidin-HRP conjugate, TMB substrate, stop solution, wash buffer concentrate, and sample/standard diluent. Refer to the kit insert or datasheet for the exact component list and storage requirements.
This kit uses colorimetric (TMB/HRP) detection and requires a standard microplate absorbance reader capable of measuring at 450 nm. A reference wavelength of 570 nm or 630 nm is recommended to reduce background. No specialized fluorescence or luminescence reader is needed. Ensure the instrument is calibrated and the plate is clean and free of condensation before reading.
Tissue samples may contain endogenous or exogenous proteases during processing, leading to degradation of extracted proteins. Therefore, it's necessary to add protease inhibitors during processing to ensure the integrity of target proteins. If customers can keep samples cold and handle them quickly during processing, omitting the protease inhibitor may not have a significant effect. After preparation, samples should be tested promptly or immediately aliquoted and frozen at -20°C or -80°C.
What is the range of enzyme activity of your IL-2 freeze-dried powder
What is the principle of adding stop solution to stop color reaction in ELISA experiment?
Can’t Find What You’re Looking For? We can help you source the best match or customize an ELISA solution for your study. Options may include alternative target synonyms, different species reactivity, sample type/matrix compatibility (serum/plasma/lysate/supernatant), assay format (sandwich/competitive), sensitivity/range, detection chemistry (colorimetric/fluorescent/chemiluminescent), plate format (pre-coated/uncoated, strips vs full plate), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
High-phytate/low-calcium diet is a risk factor for crystal nephropathies, renal phosphate wasting, and bone loss (2020) eLife. 10.7554/eLife.52709
Aerobic exercise prevents renal osteodystrophy via irisin-activated osteoblasts (2025) JCI Insight. 10.1172/jci.insight.184468
Relationship of Fibroblast Growth Factor 23 Serum Levels with Disease Characteristics in Systemic Lupus Erythematosus Patients (2023) Biomolecules. 10.3390/biom13081222
Roxadustat Increases Markers of Calcification in Patients with End-Stage Kidney Disease: Prospective Cohort Study (2025) JOURNAL OF BONE AND MINERAL RESEARCH. 10.1093/jbmr/zjaf032
Kernelized k-Local Hyperplane Distance Nearest-Neighbor Model for Predicting Cerebrovascular Disease in Patients With End-Stage Renal Disease (2021) Frontiers in Neuroscience. 10.3389/fnins.2021.773208
Intra-cardiac and peripheral levels of biochemical markers of fibrosis in patients undergoing catheter ablation for atrial fibrillation (2017) EUROPACE. 10.1093/europace/euw315
Body composition, adipokines, FGF23-Klotho and bone in kidney transplantation: Is there a link? (2021) JOURNAL OF NEPHROLOGY. 10.1007/s40620-021-00972-9
Predictive value of bone metabolism markers in the progression of diabetic kidney disease: a cross-sectional study (2024) Frontiers in Endocrinology. 10.3389/fendo.2024.1489676
The FGF23–Klotho axis promotes microinflammation in chronic kidney disease (2024) CYTOKINE. 10.1016/j.cyto.2024.156781
Correlation study of FGF23/D-serine in maintenance hemodialysis patients with combined hearing impairment (2023) PLoS One. 10.1371/journal.pone.0280378
Vitreous Olink Proteomics Uncovers Novel Inflammatory Proteins in Patients with Proliferative Diabetic Retinopathy (2025) JOURNAL OF PROTEOME RESEARCH. 10.1021/acs.jproteome.5c00394
Novel Biomarkers in Evaluating Cardiac Function in Patients on Hemodialysis—A Pilot Prospective Observational Cohort Study (2024) Diagnostics. 10.3390/diagnostics14060664
The roles of Klotho and FGF-23 in bipolar manic episode (2023) European Review for Medical and Pharmacological Sciences. 10.26355/eurrev_202310_34078
An evaluation of both serum Klotho/FGF-23 and apelin-13 for detection of diabetic nephropathy (2023) Hormones-International Journal of Endocrinology and Metabolism. 10.1007/s42000-023-00464-4
Development of a nomogram for predicting incident heart failure and all-cause mortality in patients with chronic kidney disease: a 3-year follow-up study (2026) Frontiers in Medicine. 10.3389/fmed.2026.1784717
Association of serum 25-hydroxyvitamin D3, fibroblast growth factor-23, and C1q/tumor necrosis factor-related protein-3 with coronary artery calcification in nondialysis chronic kidney disease patients (2023) RENAL FAILURE. 10.1080/0886022X.2023.2220412
The Association of Fibroblast Growth Factor 23 with Arterial Stiffness and Atherosclerosis in Patients with Autosomal Dominant Polycystic Kidney Disease (2018) KIDNEY & BLOOD PRESSURE RESEARCH. 10.1159/000492244
The correlation between fibroblast growth factor-23 and ESRD patients with hearing impairment (2021) PeerJ. 10.7717/peerj.12295
Serum 25(OH)D Concentration and Cardiovascular Disease Risk Markers Among Middle-Aged Healthy and Type 2 Diabetic Subjects (2021) HORMONE AND METABOLIC RESEARCH. 10.1055/a-1534-2747
Association of plasma neutrophil gelatinase-associated lipocalin with parameters of CKD–MBD in maintenance hemodialysis patients (2021) JOURNAL OF BONE AND MINERAL METABOLISM. 10.1007/s00774-021-01248-9
Original research: Fibroblast growth factor 23 in children with or without heart failure: a prospective study (2023) BMJ Paediatrics Open. 10.1136/bmjpo-2022-001753
Baseline fibroblast growth factor 23 predicts incident heart failure and cardiovascular mortality in patients with chronic kidney disease: A 3-year follow-up study (2024) IJC Heart & Vasculature. 10.1016/j.ijcha.2024.101587
Association Between FGF-23 Levels and Risk of Fracture in Women With Systemic Sclerosis (2020) JOURNAL OF CLINICAL DENSITOMETRY. 10.1016/j.jocd.2020.05.010
From heart to kidney: FGF23, SuPAR, and NAG as early biomarkers of cardiorenal syndrome in acute heart failure (2026) BMC Cardiovascular Disorders. 10.1186/s12872-026-05777-x
A Self-Representation-Based Fuzzy SVM Model for Predicting Vascular Calcification of Hemodialysis Patients (2021) Computational and Mathematical Methods in Medicine. 10.1155/2021/2464821
